R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 39 PLN -1.27% Market Closed
Market Cap: 901.7m PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Intrinsic Value

RVU's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RVU stock under the Base Case scenario is 42.31 PLN. Compared to the current market price of 39 PLN, Ryvu Therapeutics SA is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RVU Intrinsic Value
42.31 PLN
Undervaluation 8%
Intrinsic Value
Price
R
Worst Case
Base Case
Best Case

Valuation History
Ryvu Therapeutics SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for RVU cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about RVU?
Bearish
Neutral
Bullish

Fundamental Analysis

39 PLN
-1.27%
-1.27%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Ryvu Therapeutics SA
PL
Life Sciences Tools & Services
Market Cap
901.5m PLN
IPO
Jul 14, 2011
Employees
186
Poland
Market Cap
901.5m PLN
Industry
Life Sciences Tools & Services
IPO
Jul 14, 2011
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Ryvu Therapeutics SA

Provide an overview of the primary business activities
of Ryvu Therapeutics SA.

What unique competitive advantages
does Ryvu Therapeutics SA hold over its rivals?

What risks and challenges
does Ryvu Therapeutics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ryvu Therapeutics SA.

Provide P/S
for Ryvu Therapeutics SA.

Provide P/E
for Ryvu Therapeutics SA.

Provide P/OCF
for Ryvu Therapeutics SA.

Provide P/FCFE
for Ryvu Therapeutics SA.

Provide P/B
for Ryvu Therapeutics SA.

Provide EV/S
for Ryvu Therapeutics SA.

Provide EV/GP
for Ryvu Therapeutics SA.

Provide EV/EBITDA
for Ryvu Therapeutics SA.

Provide EV/EBIT
for Ryvu Therapeutics SA.

Provide EV/OCF
for Ryvu Therapeutics SA.

Provide EV/FCFF
for Ryvu Therapeutics SA.

Provide EV/IC
for Ryvu Therapeutics SA.

Show me price targets
for Ryvu Therapeutics SA made by professional analysts.

What are the Revenue projections
for Ryvu Therapeutics SA?

How accurate were the past Revenue estimates
for Ryvu Therapeutics SA?

What are the Net Income projections
for Ryvu Therapeutics SA?

How accurate were the past Net Income estimates
for Ryvu Therapeutics SA?

What are the EPS projections
for Ryvu Therapeutics SA?

How accurate were the past EPS estimates
for Ryvu Therapeutics SA?

What are the EBIT projections
for Ryvu Therapeutics SA?

How accurate were the past EBIT estimates
for Ryvu Therapeutics SA?

Compare the revenue forecasts
for Ryvu Therapeutics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ryvu Therapeutics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ryvu Therapeutics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ryvu Therapeutics SA compared to its peers.

Compare the P/E ratios
of Ryvu Therapeutics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Ryvu Therapeutics SA with its peers.

Analyze the financial leverage
of Ryvu Therapeutics SA compared to its main competitors.

Show all profitability ratios
for Ryvu Therapeutics SA.

Provide ROE
for Ryvu Therapeutics SA.

Provide ROA
for Ryvu Therapeutics SA.

Provide ROIC
for Ryvu Therapeutics SA.

Provide ROCE
for Ryvu Therapeutics SA.

Provide Gross Margin
for Ryvu Therapeutics SA.

Provide Operating Margin
for Ryvu Therapeutics SA.

Provide Net Margin
for Ryvu Therapeutics SA.

Provide FCF Margin
for Ryvu Therapeutics SA.

Show all solvency ratios
for Ryvu Therapeutics SA.

Provide D/E Ratio
for Ryvu Therapeutics SA.

Provide D/A Ratio
for Ryvu Therapeutics SA.

Provide Interest Coverage Ratio
for Ryvu Therapeutics SA.

Provide Altman Z-Score Ratio
for Ryvu Therapeutics SA.

Provide Quick Ratio
for Ryvu Therapeutics SA.

Provide Current Ratio
for Ryvu Therapeutics SA.

Provide Cash Ratio
for Ryvu Therapeutics SA.

What is the historical Revenue growth
over the last 5 years for Ryvu Therapeutics SA?

What is the historical Net Income growth
over the last 5 years for Ryvu Therapeutics SA?

What is the current Free Cash Flow
of Ryvu Therapeutics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ryvu Therapeutics SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ryvu Therapeutics SA

Current Assets 295.8m
Cash & Short-Term Investments 247.5m
Receivables 33.2m
Other Current Assets 15m
Non-Current Assets 107.4m
Long-Term Investments 23.5m
PP&E 74.2m
Intangibles 7.9m
Other Non-Current Assets 1.9m
Current Liabilities 97.5m
Accounts Payable 28.3m
Accrued Liabilities 11.3m
Other Current Liabilities 57.9m
Non-Current Liabilities 127.9m
Long-Term Debt 80.6m
Other Non-Current Liabilities 47.3m
Efficiency

Earnings Waterfall
Ryvu Therapeutics SA

Revenue
63.6m PLN
Cost of Revenue
-22.7m PLN
Gross Profit
40.9m PLN
Operating Expenses
-145.9m PLN
Operating Income
-104.9m PLN
Other Expenses
790k PLN
Net Income
-104.1m PLN

Free Cash Flow Analysis
Ryvu Therapeutics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RVU Profitability Score
Profitability Due Diligence

Ryvu Therapeutics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Positive 1-Year Revenue Growth
Declining ROE
22/100
Profitability
Score

Ryvu Therapeutics SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

RVU Solvency Score
Solvency Due Diligence

Ryvu Therapeutics SA's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
64/100
Solvency
Score

Ryvu Therapeutics SA's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 82.06 PLN with a low forecast of 69.19 PLN and a high forecast of 104.27 PLN.

Lowest
Price Target
69.19 PLN
77% Upside
Average
Price Target
82.06 PLN
110% Upside
Highest
Price Target
104.27 PLN
167% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RVU?

Click here to dive deeper.

Dividends

Ryvu Therapeutics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for RVU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one RVU stock?

The intrinsic value of one RVU stock under the Base Case scenario is 42.31 PLN.

Is RVU stock undervalued or overvalued?

Compared to the current market price of 39 PLN, Ryvu Therapeutics SA is Undervalued by 8%.

Back to Top